UNSPSC 51182201: Dinoprostone

This classification denotes a prostaglandin analogue with the molecular formula C20H32O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7Q1JQR04M, chemically known as u,12, 062 but generally known as dinoprostone, which bears US NIH Compound Identifier 158. European Medicines Agency schedules Dinoprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07195MIG.

UNSPSC 51182201 Dinoprostone is a Commodity code covering a specific prostaglandin pharmaceutical product; state and local governments procure dinoprostone primarily through cooperative purchasing agreements that bundle multiple generic and branded pharmaceuticals, rather than through single-product solicitations. The recent activity shows dinoprostone being sought as part of broader multi-source pharmaceutical portfolios acquired by state health departments, corrections systems, Medicaid agencies, and public hospital networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the dominant issuing body visible in current activity, leveraging its cooperative vehicle to aggregate demand across participating states including Oregon and other member jurisdictions.

The geographic footprint centers on Minnesota and Oregon, with dinoprostone demand flowing through MMCAP's multistate purchasing framework. The most recent representative opportunity is MMCAP's RFP S1070000015802, posted January 20, 2026, with a response deadline of March 26, 2026, which seeks generic multi-source pharmaceuticals and OTC products including dinoprostone to be sourced through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must hold cGMP and Drug Supply Chain Security Act (DSCSA) certifications, maintain relationships with at least two of the three wholesalers with chargeback systems, and comply with a 3 percent administrative fee; pricing is weighted at 75 percent of the evaluation, with fixed pricing, EDI capability, and format compliance making up the remainder. Awarded contracts are set to become effective July 1, 2026, with a two-year initial term and optional extensions at MMCAP's discretion, though specific contract values are not disclosed.